Considering that different IL1RAP-targeting agents have been developed for several cancer indications (for example Nadunolimab, a monoclonal IL1RAP antibody exhibiting antibody-dependent cellular cytotoxicity and receptor blocking activities, as well as CAR-T cells targeting IL1RAP under early clinical development [71–73]), our work will help position these novel therapies in AML by identifying AML patients most likely to respond to IL1RAP-targeting immunotherapeutic strategies and possibly provide logical grounds for combinatorial treatments with existing agents. The gene discussed is IL1RAP; the disease is cancer.